All In Biotech

Drug Trial Radar · NCT00144170

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

882

Actual

Start

Feb 2003

Primary completion

Oct 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients. Patients must have a viral load \> =1000 cells/mL, and genotype indicating at least one resistance conferring protease inhibitor-mutation as determined from a predefined panel of mutations. Any CD4+ count is acceptable.

Conditions

  • HIV Infections

Interventions

  • Tipranavir (with low dose ritonavir)Drug

  • Comparator protease inhibitor(CPI)/low dose ritonavir(r)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Response at Week 48Time frame: after 48 weeks of treatment
  2. Time to Treatment Failure Through 48 Weeks of TreatmentTime frame: after 48 weeks of treatment

Locations

174 sites in 17 countries. Site status is shown where the registry gives one.

  • 1182.48.5401 Fundación Huésped

    Buenos Aires, Argentina

  • 1182.48.5402 Fundación Huésped

    Buenos Aires, Argentina

  • 1182.48.5403 Servicio de Infecciosas

    Buenos Aires, Argentina

  • 1182.48.5404 Servicio de Infecciosas

    Buenos Aires, Argentina

  • 1182.48.5405 Hospital Muniz

    Buenos Aires, Argentina

  • 1182.48.5406 Servicio de Immunocomprometido

    Buenos Aires, Argentina

  • 1182.48.4301 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1182.48.3209 Boehringer Ingelheim Investigational Site

    Antwerp, Belgium

  • 1182.48.3201 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1182.48.3202 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1182.48.3206 Boehringer Ingelheim Investigational Site

    Charleroi, Belgium

  • 1182.48.3207 Boehringer Ingelheim Investigational Site

    Ghent, Belgium

  • 1182.48.3210 Boehringer Ingelheim Investigational Site

    Luxembourg, Belgium

  • 1182.48.5512 Cidade Universitária Zeferino Vaz-Clínica Médica FCM

    Campinas - SP, Brazil

  • 1182.48.5505 Instituto A-Z de Pesquisa e Ensino da PUC

    Curitiba - PR, Brazil

  • 1182.48.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde

    Nova Iguaçu - RJ, Brazil

  • 1182.48.5502 Fundação Oswaldo Cruz

    Rio de Janeiro - RJ, Brazil

  • 1182.48.5509 Universidade Federal do Rio de Janeiro

    Rio de Janeiro - RJ, Brazil

  • 1182.48.5511 Universidade Federal da Bahia-Unidade Docente Assistencial d

    Salvador - BA, Brazil

  • 1182.48.5501 Clínica de Doenças Parasitárias e Infecciosas-Hospital Dia

    São Paulo - SP, Brazil

  • 1182.48.5503 I.I. Emilio Ribas - Moléstias Infecciosas

    São Paulo - SP, Brazil

  • 1182.48.5504 Hospital do Servidor Público Estadual - IAMSPE

    São Paulo - SP, Brazil

  • 1182.48.5506 Centro de Referência e Treinamento - DST/AIDS

    São Paulo - SP, Brazil

  • 1182.48.5508 I.I. Emilio Ribas

    São Paulo - SP, Brazil

  • 1182.48.5510 INCOR e Hospital das Clínicas da Universidade de São Paulo

    São Paulo - SP, Brazil

  • 1182.48.5513 UNIFESP - Centro de Pesquisa Clinica

    São Paulo - SP, Brazil

  • 1182.48.4505 Boehringer Ingelheim Investigational Site

    Aarhus N, Denmark

  • 1182.48.4502 Boehringer Ingelheim Investigational Site

    Hvidovre, Denmark

  • 1182.48.4501 Boehringer Ingelheim Investigational Site

    København Ø, Denmark

  • 1182.48.4504 Boehringer Ingelheim Investigational Site

    Odense C, Denmark

  • 1182.48.3311 Boehringer Ingelheim Investigational Site

    Besançon, France

  • 1182.48.3307 Boehringer Ingelheim Investigational Site

    Bordeaux, France

  • 1182.48.3317 Boehringer Ingelheim Investigational Site

    Bordeaux, France

  • 1182.48.3302 Boehringer Ingelheim Investigational Site

    Caen, France

  • 1182.48.3303 Boehringer Ingelheim Investigational Site

    Clamart, France

  • 1182.48.3305 Boehringer Ingelheim Investigational Site

    Le Kremlin-Bicêtre, France

  • 1182.48.3304 Boehringer Ingelheim Investigational Site

    Lyon, France

  • 1182.48.3322 Boehringer Ingelheim Investigational Site

    Lyon, France

  • 1182.48.3308 Boehringer Ingelheim Investigational Site

    Marseille, France

  • 1182.48.3309 Boehringer Ingelheim Investigational Site

    Marseille, France

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.